Medicines Co. buys Curacyte subsidiary

The Medicines Company is buying Curacyte subsidiary Curacyte Discovery for €14.5 million up front. Curacyte Discovery is developing a serine protease inhibitor in the area of hemostasis and anti-coagulation. Its lead candidate, CU-2010, a treatment for preventing surgical blood loss, is expected to enter Phase I trials by the end of this year. The Medicines Company gains CU-2010 as part of the deal, and Curacyte could receive an additional payment of €10.5 million if the drug proceeds to Phase II clinical development--Curacyte could also earn commercial milestone and royalty payments.

"The transaction will help the parent company, Curacyte, to focus on fully developing its key product, hemoximer, in a pivotal Phase III study in distributive shock," said Dr. Helmut Giersiefen, Curacyte's CEO.

 - here's the release

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.